 SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 PRNewswire -- A Duke University-led study published in bioRxiv showed that Vaxart, Inc.s NASDAQ: VXRT investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model. 